- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01249469
Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011
Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 on Solar Lentigines by Harmonic Generation Microscopy
Background: Solar lentigines are a common dermatologic condition that manifest as circumscribed single or multiple brownish macules usually located on sun-exposed skin such as face, hands or forearms. An effective, safe, daily-use, homecare whitening product may alleviate the cosmetic concerns for the general population. The efficacy and safety of the previous generation BEX-2009 (Blanc Expert Spot Eraser, L'Oreal, France), a whitening cosmetic product containing ellagic acid, salicylic acid, licorice root extract, etc., has been established in Caucasian and Asian populations with facial solar lentigines.
Objective: The purpose of this placebo-controlled, single-center study is 1) to evaluate the efficacy of the new generation whitening cosmetic product BEX-2011 (Ultimate Whitening Spot Eraser, L'Oreal, France) in the improvement of solar lentigines on the dorsum of hands or forearms, and 2) to evaluate the efficacy of BEX-2011 by harmonic generation microscopy to obtain information of the epidermal melanin continuum, compared to other standard tools for melanin measurement.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yi-Hua Liao Liao, M.D PhD
- Phone Number: 886-2-23562141
- Email: yihualiao@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Yi-Hua Liao, MD, PhD
- Phone Number: 886-2-23562141
- Email: yihualiao@ntu.edu.tw
-
Principal Investigator:
- Yi-Hua Liao, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 40-65 years old Asian women (skin types III to IV)
- With ≥10 solar lentigines on the forearms or dorsum of hands
- With at least one to three lesions ≥4 mm on the left or right forearm/ dorsum of hand, respectively, which are flat and are at the same pigmentation degree according to the color chart.
Exclusion Criteria:
- Having major treatment, including topical hydroquinone or tretinoin, cryotherapy, electrosurgery, trichloroacetic acid application, laser or intense pulsed light, in the 3 months before the beginning of the study
- Past history of allergy to whitening cosmetic products
- Past history of atopic dermatitis
- Habit of going to the tanning salon or frequent sun exposure longer than 4 hours per day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Vehicle
Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit.
The product is applied on one side of the hand.
|
Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit.
The product is applied on one side of the hand
Other Names:
|
Experimental: Skin whitening cosmetic product
Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit.
The product is applied on one side of the hand.
|
Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit.
The product is applied on one side of the hand
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the mean reduction of darkness from baseline in target area after treatment
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the difference of darkness between the treated spots and the control spots
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yi-Hua Liao, MD, PhD, Department of Dermatology, National Taiwan University Hospital
Publications and helpful links
General Publications
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201003024M
- NTUH201003024M (Registry Identifier: NTUH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solar Lentigines
-
Brazilan Center for Studies in DermatologyCompleted
-
University of ZurichCompletedSolar LentiginesSwitzerland
-
Panion & BF Biotech Inc.CompletedSolar LentiginesTaiwan
-
Shahid Beheshti University of Medical SciencesCompletedSolar LentiginesIran, Islamic Republic of
-
Cynosure, Inc.CompletedFacial Solar LentiginesUnited States
-
Mahidol UniversityCompleted
-
Zealand University HospitalCompleted
-
Laval UniversityCompleted
-
The Maas ClinicMedicis Pharmaceutical CorporationCompletedIntrinsic Aging of Skin | Solar ElastosisUnited States
Clinical Trials on skin whitening cosmetic product
-
SVR GroupNot yet recruiting
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Amazentis SAproDERM GmbHCompleted
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Dr. August Wolff GmbH & Co. KG ArzneimittelproDERM Institut für Angewandte Dermatologische Forschung GmbH; Microscopy...Completed
-
Massachusetts General HospitalCompletedHyperpigmentationUnited States
-
Dr. August Wolff GmbH & Co. KG ArzneimittelSIT Skin Investigation and Technology Hamburg GmbHCompleted
-
Dr. August Wolff GmbH & Co. KG ArzneimittelSIT Skin Investigation and Technology Hamburg GmbHCompleted
-
Pierre Fabre Dermo CosmetiqueCompleted